跳至主要内容
临床试验/NCT04506671
NCT04506671招募中不适用

A Prospective, Non-randomized, in Parallel Groups Study Evaluating the Efficacy and Safety of Percutaneous Cryoablation and Partial Nephrectomy in Localized T1b Renal Tumor

I.M. Sechenov First Moscow State Medical University2 个研究点 分布在 2 个国家目标入组 142 人开始时间: 2020年5月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
142
试验地点
2
主要终点
Local recurrence

研究概览

简要总结

The aim of our study is to assess the long-term oncological and functional outcomes of cryoablation for T1b renal tumors, as well as such important parameters as the patient's quality of life after treatment, and to compare the results with those after partial nephrectomy.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • CT-confirmed renal mass > 4 to 7 cm (T1b)

排除标准

  • Multiple renal tumors;
  • Recurrence of renal tumor;
  • Intolerance to iodine-containing contrast agents;
  • Pregnancy;
  • Patients with Bosniak 4 cysts
  • Presence of other oncological diseases;
  • Impossibility of organ-preserving treatment due to the proximity of the tumor to the vessels or the calyx-pelvic system
  • Absence of malignant pathology based on prior biopsy.

结局指标

主要结局

Local recurrence

时间窗: 5 years

Local recurrance will be evaluated with CT after 6 months, a year, then annually - up to 5 years after the treatment

次要结局

  • Metastatic progression(5 years)
  • Blood loss(12 months)
  • Length of hospital stay(1 month)
  • Quality of life assessment: The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30)(5 years)
  • Pain score(5 years)
  • Renal function(5 years)
  • Rate of adverse events(3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dmitry Enikeev, MD, PhD

Deputy Director for Research

I.M. Sechenov First Moscow State Medical University

研究点 (2)

Loading locations...

相似试验